Semaglutide Dosing Protocol: GLP-1 Research Guide

Also known as: Ozempic, Wegovy, Rybelsus

metabolic

Research Reference Only

This information is for educational purposes only. Semaglutide is not FDA approved for human use. The protocols listed are summaries of published research studies and do not constitute medical advice. Always consult a licensed healthcare provider.

Overview

Semaglutide is a GLP-1 receptor agonist that mimics the hormone glucagon-like peptide-1. It has been extensively studied for type 2 diabetes and obesity, showing significant effects on weight loss and glycemic control.

Mechanisms of Action

Activates GLP-1 receptors in pancreas

Enhances insulin secretion in glucose-dependent manner

Suppresses glucagon release

Slows gastric emptying

Reduces appetite via hypothalamic pathways

Research Protocols

The following protocols are summaries of published research studies. They are presented for educational purposes only and do not constitute medical advice.

Protocol Name	Source	Dose	Frequency	Duration	Route	Evidence	Link
STEP 1 Obesity Trial	published study	2.4 mg	Weekly	68 weeks	Subcutaneous	human

Important Warnings

Safety Considerations

Requires gradual dose titration to minimize GI side effects
Contraindicated in personal/family history of medullary thyroid carcinoma
May cause gallbladder issues
Not studied with other weight loss products